ME02105B - Modulatori atp-vezujucih kasetnih transportera - Google Patents
Modulatori atp-vezujucih kasetnih transporteraInfo
- Publication number
- ME02105B ME02105B MEP-2015-37A MEP3715A ME02105B ME 02105 B ME02105 B ME 02105B ME P3715 A MEP3715 A ME P3715A ME 02105 B ME02105 B ME 02105B
- Authority
- ME
- Montenegro
- Prior art keywords
- disease
- compound
- abc transporter
- activity
- composition
- Prior art date
Links
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title claims 9
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000025237 Polyendocrinopathy Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical group C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims 1
- 230000002988 nephrogenic effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Spoj koji je:
2. Farmaceutski sastav koji sadrži (i) spoj prema patentnom zahtjevu 1; i (ii) farmaceutski prihvatljivnosač.
3. Sastav prema patentnom zahtjevu 2, naznačen time da nadalje sadrži dodatno sredstvo izabrano od mukolitičkog sredstva, bronhodilatatora, antibiotika, anti-infektivnog sredstva, protu-upalnog sredstva, CFTR korektora, CFTR pojačivača, ili nutritivnog sredstva.
4. Sastav prema patentom zahtjevu 3, naznačen time da je dodatno sredstvo CFTR pojačivač.
5. Sastav prema patentom zahtjevu 4, naznačen time da je pojačivač N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid.
6. In vitro metoda povećanja broja funkcionalnih ABC transportera u membrani satnice in vitro, koji sadrži korak uspostavljanja kontakta navedene stanice sa spojem koji je:
7. In vitro metoda prema patentnom zahtjevu 6, naznačen time da je ABC transporter CFTR.
8. Spoj koji je: za upotrebu u liječenju stanja, bolesti ili poremećaja kod pacijenta a koji su implicirani aktivnošću ABC transportera, pri čemu je navedeno stanje, bolest ili poremećaj izabrano od cistične fibroze, nasljednog emfizema, nasljedne hemokromatoze, fibrinolize-nedostataka koagulacije, kao što su nedostatak proteina C, Tip 1 nasljedni angioedem, nedostaci prerade lipida, kao što su familijarna hiperkolesterolemija, Tip 1 hilomikronemija, abetalipoproteinemija, bolesti lizosomalnog nakupljanja, kao što je 1-stanična bolest/Pseudo-Hurler, mukopolisaharidoze, Sandhof/Tay-Sachs, Crigler-Najjar tip II, poliendokrinopatija/hiperinsulinemija, dijabetes melitus, Laronov patuljasti rast, nedostatak mijeloperoksidaze, primarni hipoparatireoidizam, melanom, Glikanozis CDG tip 1, nesljedni emfizem, kongenitalni hipertireoidizam, osteogenezis imperfekta, nasljedna hipofibrinogenemia, ACT nedostatak, dijabetes insipidus (DI), neurohipofizealni DI, nefrogeni DI, tzv. "Charcot-Marie Tooth sindrom", tzv. "Perlizaeus-Merzbacher bolest", neurodegenerativne bolesti kao što su Alzheimerova bolest, Parkinsonova bolest, amiotrofična lateralna skleroza, progresivna supranuklearna paraliza, Pikova bolest, nekoliko poliglutamin neuroloških poremećaja kao što su, Hantingtonova bolest, spinocerebelarna ataksija tip I, spinalna i bulbarna mišična atrofija, dentatorubralna-palidolizinska atrofija i miotonična distrofija, kao i spongioformne encefalopatije, kao što su nasljedna Creutzfeldt-Jakobova bolest, Fabrijeva bolest, Gerstmann-Sträussler-Scheinkerov sindrom, COPD, bolest suhog oka, Sjögrenov sindrom.
9. Spoj za upotrebu prema patentnom zahtjevu 8, naznačen time da je stanje, bolest ili poremećaj cistična fibroza.
10. Oprema za upotrebu u mjerenju aktivnosti ABC transportera ili njegovog fragmenta u biološkom uzorku in vitro ili in vivo, koji sadrži: (i) prvi sastav koji sadrži spoj prema patentnom zahtjevu 1; i (ii) instrukcije za: a) kontaktiranje sastava s biološkim uzorkom; b) mjerenje aktivnosti navedenog ABC transportera ili njegovog fragmenta.
11. Oprema za upotrebu prema patentnom zahtjevu 10, naznačena time da nadalje sadrži instrukcije za a) kontaktiranje dodatnog sastava s biološkim uzorkom; b) mjerenje aktivnosti navedenog ABC transportera ili njegovog fragmenta u prisutnosti navedenog dodatnog spoja, i c) usporedba aktivnosti ABC transportera u prisutnosti dodatnog spoja s gustoćom ABC transportera u prisutnosti navedene prvog sastava.
12. Oprema za upotrebu prema patentnom zahtjevu 10, naznačena time da se oprema koristi za mjerenje gustoće CPTR.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11214508P | 2008-11-06 | 2008-11-06 | |
| US11215208P | 2008-11-06 | 2008-11-06 | |
| PCT/US2008/012689 WO2010053471A1 (en) | 2008-11-06 | 2008-11-12 | Modulators of atp-binding cassette transporters |
| EP08876364.4A EP2365972B1 (en) | 2008-11-06 | 2008-11-12 | Modulators of atp-binding cassette transporters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02105B true ME02105B (me) | 2015-10-20 |
Family
ID=40933810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-37A ME02105B (me) | 2008-11-06 | 2008-11-12 | Modulatori atp-vezujucih kasetnih transportera |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP2365972B1 (me) |
| JP (4) | JP5600322B2 (me) |
| KR (3) | KR20160013251A (me) |
| CN (2) | CN102272127A (me) |
| AU (1) | AU2008363828B2 (me) |
| BR (1) | BRPI0823228B8 (me) |
| CA (1) | CA2742821C (me) |
| CL (1) | CL2011001027A1 (me) |
| CY (2) | CY1116067T1 (me) |
| DK (1) | DK2365972T3 (me) |
| ES (1) | ES2532753T3 (me) |
| FR (1) | FR19C1017I2 (me) |
| HK (1) | HK1216526A1 (me) |
| HR (1) | HRP20150288T1 (me) |
| HU (1) | HUS1900015I1 (me) |
| IL (3) | IL212737A (me) |
| LT (1) | LTC2365972I2 (me) |
| LU (1) | LUC00110I2 (me) |
| ME (1) | ME02105B (me) |
| MX (2) | MX357497B (me) |
| NL (1) | NL300984I9 (me) |
| NO (1) | NO2019015I1 (me) |
| NZ (2) | NZ592694A (me) |
| PL (1) | PL2365972T3 (me) |
| PT (1) | PT2365972E (me) |
| RS (1) | RS53868B1 (me) |
| RU (1) | RU2013157877A (me) |
| SI (1) | SI2365972T1 (me) |
| UA (1) | UA121188C2 (me) |
| WO (1) | WO2010053471A1 (me) |
| ZA (1) | ZA201103883B (me) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| PL2404919T3 (pl) | 2005-11-08 | 2014-01-31 | Vertex Pharma | Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP |
| DK1993360T3 (en) | 2005-12-28 | 2017-05-22 | Vertex Pharma | SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE |
| EP3091011B1 (en) | 2006-04-07 | 2017-12-27 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| RS55360B1 (sr) | 2007-12-07 | 2017-03-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina |
| KR20160040745A (ko) | 2007-12-07 | 2016-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| MX357497B (es) * | 2008-11-06 | 2018-07-11 | Vertex Pharma | Moduladores de transportadores de casete de union a atp. |
| HRP20151137T1 (hr) | 2009-03-20 | 2015-11-20 | Vertex Pharmaceuticals Incorporated | Postupak za dobivanje modulatora transmembranskog regulatora vodljivosti cistiäśne fibroze |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| NZ700556A (en) * | 2010-03-25 | 2016-04-29 | Vertex Pharma | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
| EP4005559B1 (en) | 2010-04-07 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| NZ603044A (en) * | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| NZ603043A (en) * | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| EP3138563A1 (en) * | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
| SG10201505700QA (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
| RU2013112937A (ru) * | 2010-08-23 | 2014-09-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение |
| IN2014KN00885A (me) * | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
| RU2644723C2 (ru) | 2012-01-25 | 2018-02-13 | Вертекс Фармасьютикалз Инкорпорейтед | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| IL265430B2 (en) | 2012-02-27 | 2024-08-01 | Vertex Pharma | Pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamode and uses thereof |
| AR092857A1 (es) | 2012-07-16 | 2015-05-06 | Vertex Pharma | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas |
| EP2970468B1 (en) | 2013-03-13 | 2021-07-07 | Novartis AG | Notch2 binding molecules for treating respiratory diseases |
| MX365950B (es) | 2013-03-13 | 2019-06-19 | Flatley Discovery Lab Llc | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. |
| RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
| US10206877B2 (en) | 2014-04-15 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| US10864213B2 (en) | 2014-05-12 | 2020-12-15 | Verona Pharma Plc | Treatment |
| GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| MX2017004543A (es) | 2014-10-06 | 2017-10-04 | Vertex Pharma | Moduladores de regulador de conductancia transmembranal de fibrosis quística. |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| HRP20211194T1 (hr) | 2014-11-18 | 2021-10-29 | Vertex Pharmaceuticals Inc. | Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti |
| AU2015374342A1 (en) | 2014-12-31 | 2017-07-20 | Auspex Pharmaceuticals, Inc. | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator |
| GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
| HK1249893A1 (zh) | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| CN105153106B (zh) * | 2015-09-02 | 2017-08-25 | 阜新奥瑞凯新材料有限公司 | 一种2,2‑二氟胡椒酸甲酯的制备方法 |
| GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
| WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
| JP6601365B2 (ja) | 2016-07-27 | 2019-11-06 | 株式会社デンソー | 制御システム |
| UA124708C2 (uk) | 2016-09-30 | 2021-11-03 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019161078A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN111763198B (zh) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | 一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法 |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| EP4013759A1 (en) | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| JP7752106B2 (ja) | 2019-08-14 | 2025-10-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒモジュレータの結晶形態 |
| EP4099991A4 (en) * | 2020-02-05 | 2024-06-26 | Laurus Labs Limited | NEW PROCESSES FOR PREPARING TEZACAFTOR |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| WO2022076627A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225761A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076624A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3197683A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076621A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225763A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL301756A (en) | 2020-10-07 | 2023-05-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2023552828A (ja) | 2020-12-10 | 2023-12-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| KR20240144973A (ko) | 2022-02-03 | 2024-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| CA3249865A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR PREPARATION AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12,3,1,12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL |
| CN118974059A (zh) | 2022-02-08 | 2024-11-15 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| CR20240457A (es) | 2022-04-06 | 2024-12-11 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3253977A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | SOLID FORMS OF MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP3091011B1 (en) | 2006-04-07 | 2017-12-27 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| MX357497B (es) * | 2008-11-06 | 2018-07-11 | Vertex Pharma | Moduladores de transportadores de casete de union a atp. |
-
2008
- 2008-11-12 MX MX2013012665A patent/MX357497B/es unknown
- 2008-11-12 KR KR1020167000956A patent/KR20160013251A/ko not_active Ceased
- 2008-11-12 BR BRPI0823228A patent/BRPI0823228B8/pt active IP Right Grant
- 2008-11-12 UA UAA201312737A patent/UA121188C2/uk unknown
- 2008-11-12 NZ NZ592694A patent/NZ592694A/xx not_active IP Right Cessation
- 2008-11-12 MX MX2011004832A patent/MX2011004832A/es active IP Right Grant
- 2008-11-12 WO PCT/US2008/012689 patent/WO2010053471A1/en not_active Ceased
- 2008-11-12 RS RS20150170A patent/RS53868B1/sr unknown
- 2008-11-12 JP JP2011535544A patent/JP5600322B2/ja active Active
- 2008-11-12 ES ES08876364.4T patent/ES2532753T3/es active Active
- 2008-11-12 HR HRP20150288TT patent/HRP20150288T1/hr unknown
- 2008-11-12 PL PL08876364T patent/PL2365972T3/pl unknown
- 2008-11-12 EP EP08876364.4A patent/EP2365972B1/en active Active
- 2008-11-12 ME MEP-2015-37A patent/ME02105B/me unknown
- 2008-11-12 SI SI200831394T patent/SI2365972T1/sl unknown
- 2008-11-12 AU AU2008363828A patent/AU2008363828B2/en active Active
- 2008-11-12 CN CN2008801326311A patent/CN102272127A/zh active Pending
- 2008-11-12 KR KR1020157006518A patent/KR101587389B1/ko active Active
- 2008-11-12 EP EP14197820.5A patent/EP2940016A1/en not_active Withdrawn
- 2008-11-12 DK DK08876364.4T patent/DK2365972T3/en active
- 2008-11-12 CA CA2742821A patent/CA2742821C/en active Active
- 2008-11-12 PT PT08876364T patent/PT2365972E/pt unknown
- 2008-11-12 NZ NZ609962A patent/NZ609962A/en unknown
- 2008-11-12 CN CN201711204617.5A patent/CN108117546A/zh active Pending
- 2008-11-12 KR KR1020117012764A patent/KR101559963B1/ko active Active
-
2011
- 2011-05-05 IL IL212737A patent/IL212737A/en active Pre-grant Review Request
- 2011-05-09 CL CL2011001027A patent/CL2011001027A1/es unknown
- 2011-05-26 ZA ZA2011/03883A patent/ZA201103883B/en unknown
-
2013
- 2013-12-25 RU RU2013157877/04A patent/RU2013157877A/ru not_active Application Discontinuation
-
2014
- 2014-07-28 IL IL233837A patent/IL233837A/en active IP Right Grant
- 2014-08-15 JP JP2014165547A patent/JP5728611B2/ja active Active
-
2015
- 2015-03-03 CY CY20151100222T patent/CY1116067T1/el unknown
- 2015-04-06 JP JP2015077925A patent/JP5905620B2/ja active Active
- 2015-06-30 IL IL239713A patent/IL239713A/en active Protection Beyond IP Right Term
-
2016
- 2016-03-16 JP JP2016052743A patent/JP2016147887A/ja active Pending
- 2016-04-15 HK HK16104342.9A patent/HK1216526A1/en unknown
-
2019
- 2019-03-13 HU HUS1900015C patent/HUS1900015I1/hu unknown
- 2019-03-15 FR FR19C1017C patent/FR19C1017I2/fr active Active
- 2019-03-21 LU LU00110C patent/LUC00110I2/fr unknown
- 2019-03-21 LT LTPA2019505 patent/LTC2365972I2/lt unknown
- 2019-04-04 NO NO2019015C patent/NO2019015I1/no unknown
- 2019-04-29 NL NL300984C patent/NL300984I9/nl unknown
- 2019-04-30 CY CY2019023C patent/CY2019023I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02105B (me) | Modulatori atp-vezujucih kasetnih transportera | |
| HRP20170458T1 (hr) | Modulatori atp - vezujućih kasetnih transportera | |
| HRP20151141T1 (hr) | Derivati piridila kao modulatori cftr | |
| HRP20210165T1 (hr) | Čvrsta disperzija amorfnog oblika (r)-1(2,2-difluorobenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamida | |
| HRP20180328T1 (hr) | FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE | |
| NZ581259A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HRP20160682T1 (hr) | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline | |
| RU2011122646A (ru) | Модуляторы переносчиков атф-связывающих кассет | |
| RU2011142297A (ru) | Модуляторы регулятора трансмембранной проводимости кистозного фиброза | |
| NZ587545A (en) | Heteroaryl derivatives as cftr modulators | |
| HRP20170847T1 (hr) | Modulatori atp - vezujućih kasetnih transportera | |
| JP2012521361A5 (me) | ||
| NZ603044A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| Yang et al. | Enhancement of amino acid detection and quantification by electrospray ionization mass spectrometry | |
| RU2008144124A (ru) | Модуляторы атф-связывающих кассетных транспортеров | |
| Briscoe et al. | Factors affecting the stability of drugs and drug metabolites in biological matrices | |
| IL273752B2 (en) | Ingredients, compounds and methods for increasing CFTR activity | |
| JP2011513321A5 (me) | ||
| RU2011120327A (ru) | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил-)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида | |
| RU2014134456A (ru) | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| Li et al. | Nanosecond photochemically promoted click chemistry for enhanced neuropeptide visualization and rapid protein labeling | |
| Perez Hurtado et al. | Deamidation of collagen | |
| Gawande et al. | Stress studies and identification of degradation products of cephalexin using LC–PDA and LC–MS/MS | |
| Möller et al. | Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO‐mimetic peptide for sports drug testing purposes | |
| Kraus et al. | Characterization of intermolecular β‐sheet peptides by mass spectrometry and hydrogen isotope exchange |